November 22, 2006Dementia and Geriatric Cognitive Disorders
Differential CSF Biomarker Levels in APOE-ε4-Positive and -Negative Patients with Memory Impairment
Authors
Discussion
Loading...
Member takes
Implication
Retrospective cohort study reveals distinct cerebrospinal fluid biomarker profiles between APOE-ε4 carriers and non-carriers with memory loss, suggesting divergent underlying disease mechanisms.
Key Points
- To examine how APOE genotype interacts with episodic memory performance, cerebrospinal fluid biomarker profiles, and longitudinal cognitive decline.
- Retrospective analysis of N=124 memory clinic patients categorized into six cohorts based on episodic memory status (severe, moderate, or no impairment via the Rey Auditory Verbal Learning Test) and APOE ε4 status (positive vs. negative).
- Measured cerebrospinal fluid levels of total tau (T-tau), phospho-tau (P-tau), and beta-amyloid (Abeta42), and monitored longitudinal cognitive decline across groups.
- Episodic memory performance correlated significantly with CSF biomarker levels only in APOE ε4-positive subjects, with no significant correlation observed in ε4-negative individuals.
- Abeta42 levels were significantly reduced in ε4-positive patients with moderate and severe memory impairment, while T-tau and P-tau levels were elevated solely in ε4-positive patients with severe memory impairment compared to all other groups.
- Cognitive decline over follow-up occurred in patients with severe baseline memory impairment regardless of whether they were APOE ε4-positive or ε4-negative.
Cite This Study
Andersson et al. (2006) studied this question.